Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032. - Wikidata - wikimedia - TriplyDB

Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032.

Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032.

http://www.wikidata.org/entity/Q34049618

about

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma Resistance to BRAF inhibitors: unraveling mechanisms and future treatment options Update on benefit of immunotherapy and targeted therapy in melanoma: the changing landscape.Signalling scaffolds and local organization of cellular behaviour Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials BRAF mutations in advanced cancers: clinical characteristics and outcomes Guiding Oncology Patients Through the Maze of Precision Medicine.In-depth genomic data analyses revealed complex transcriptional and epigenetic dysregulations of BRAFV600E in melanoma.MAGERI: Computational pipeline for molecular-barcoded targeted resequencing.In vitro treatment of melanoma brain metastasis by simultaneously targeting the MAPK and PI3K signaling pathways.Molecular alterations in clinical stage III cutaneous melanoma: Correlation with clinicopathological features and patient outcome.New strategies in melanoma: molecular testing in advanced disease.Implementation of biomarker-driven cancer therapy: existing tools and remaining gaps.Validation of the VE1 immunostain for the BRAF V600E mutation in melanoma.Targeted inhibition of BRAF kinase: opportunities and challenges for therapeutics in melanoma.The clinical response to vemurafenib in a patient with a rare BRAFV600DK601del mutation-positive melanoma.Comparative evaluation of the new FDA approved THxID™-BRAF test with High Resolution Melting and Sanger sequencing Immunohistochemistry with the anti-BRAF V600E (VE1) antibody: impact of pre-analytical conditions and concordance with DNA sequencing in colorectal and papillary thyroid carcinoma.Dramatic response to dabrafenib and trametinib combination in a BRAF V600E-mutated cholangiocarcinoma: implementation of a molecular tumour board and next-generation sequencing for personalized medicine.Comparison of testing methods for the detection of BRAF V600E mutations in malignant melanoma: pre-approval validation study of the companion diagnostic test for vemurafenib.The role of BRAF V600 mutation in melanoma Driver mutations in melanoma: lessons learned from bench-to-bedside studies Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanoma.Snowball: resampling combined with distance-based regression to discover transcriptional consequences of a driver mutation Update on Molecular Pathology of Cutaneous Melanocytic Lesions: What is New in Diagnosis and Molecular Testing for Treatment?Tumor homogeneity between primary and metastatic sites for BRAF status in metastatic melanoma determined by immunohistochemical and molecular testing Colorectal cancers from distinct ancestral populations show variations in BRAF mutation frequency CXCR3 signaling in BRAFWT melanoma increases IL-8 expression and tumorigenicity.KIAA1549: BRAF Gene Fusion and FGFR1 Hotspot Mutations Are Prognostic Factors in Pilocytic Astrocytomas.BRAF mutation is not predictive of long-term outcome in papillary thyroid carcinoma.The potential for BRAF V600 inhibitors in advanced cutaneous melanoma: rationale and latest evidence Occult oncocytic papillary thyroid carcinoma with lymphoid stroma (Warthin-like tumor): report of a case with concomitant mutations of BRAF V600E and V600K Targeting mutant BRAF in melanoma: current status and future development of combination therapy strategies The current state of targeted therapy in melanoma: this time it's personal Comparison between two widely used laboratory methods in BRAF V600 mutation detection in a large cohort of clinical samples of cutaneous melanoma metastases to the lymph nodes.BRAFV600E remodels the melanocyte transcriptome and induces BANCR to regulate melanoma cell migration.Detecting BRAF Mutations in Formalin-Fixed Melanoma: Experiences with Two State-of-the-Art Techniques.Tumor cellularity as a quality assurance measure for accurate clinical detection of BRAF mutations in melanoma.Drug targets and predictive biomarkers in the management of metastatic melanoma.Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma

P2860

Q24597152-5FF51CCA-C026-4EE2-9D55-8505835B954C Q27023596-996649A0-2CF4-4AD5-AD3B-A1BDD72E32BE Q27691824-5C463B44-AB7B-4419-8CB5-F1BD2E320F25 Q28259061-D97C01F9-7300-4FD5-8F69-9A84DDEC6504 Q28730438-1A1D2EF6-C032-48ED-81B1-7FA3F90B4EBA Q28743591-5BE1A07E-4BD5-4BC1-B807-2CE1E28C35DE Q30773132-0FFA0D21-42F9-440F-83E9-277A2381EFEC Q30936571-F54C19F7-3EE6-4E08-AF79-25E380319234 Q33642719-120EFFD7-DAA8-44EC-BBE6-B63BC2D35E49 Q33755862-BC497E66-E828-415D-95A7-240B640FF9FB Q33778554-4A61240A-DCBC-4C9D-AF62-38F949E679B6 Q33943660-076C46C8-6780-440B-8862-969DC8A4F452 Q34163458-A543DB23-F4A0-44C7-82E3-C6BAB1013833 Q34207132-1F20CE77-E2ED-4F5F-A6E8-E663FAE3A62B Q34222257-A7B11723-F7E7-4C20-99B4-A7300DF52433 Q34316552-53945F6E-E6F6-4023-A5F6-4D0175FB120A Q34469532-DACDC2CC-EEC5-45E3-8DF6-8DD6DA316DEB Q34520869-D02E0EFA-CB89-44DA-98BE-B82CA6AAB214 Q34550326-7118AC43-F6E3-45C5-A936-8D413AAD49AA Q34551705-9DD10FC6-716B-461B-BF88-27929D519039 Q34637951-45E815E0-DC47-44DB-861D-DA0CA84368CE Q34639532-C49BEB17-BC42-4A79-B4BC-3B4BB88AB03F Q34641609-EB117CF4-FF6B-4F92-8C0B-6C8562C23A6E Q34737289-7029DBDD-BEB5-452C-A586-7D7E914223AD Q34928118-6FE18BDC-A1BE-4F3D-976C-02302B87F83E Q34970350-45FCA08A-B5AF-4EB8-847D-5D19A061F739 Q34997425-E44F0885-6F3C-47D4-AC50-1C22B7D54106 Q35583851-A36F1E0A-A85B-4D36-B0EA-2CD9C263EB7D Q35751428-E60B14B5-60AC-4951-AC76-1EFFD463D0A1 Q35755353-6A445D00-4F88-4AA6-ADA7-A4F71CF5B3F0 Q35810176-D2651288-A4EF-498A-A72D-2A39B07FC0E1 Q35854453-83C1D5A4-F926-459E-B260-C7E0DB036BF5 Q35859282-C88DB31E-FA0A-4207-A390-BB2E459B5E1E Q35878248-A81E2008-3AED-4F3C-9F30-1A966EBC6EDE Q36014476-EF2E041F-4040-4F44-BAF5-D9E0BDBF54C7 Q36021702-42723B2A-5373-4F66-ACB1-30EA082D8AE8 Q36058758-BBAA5D7E-FF8E-4A11-9D6A-1B327F2F6E7B Q36276146-0F10A947-74DF-4751-9868-8432C2223B7E Q36441552-1F12AA92-6251-4EF3-BF23-4FD5CCBB38AF Q36561655-8F813E56-8151-458B-A22D-3D61A0112357

P2860

Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032.

http://www.wikidata.org/entity/Q34049618

description

2010 nî lūn-bûn

@nan

2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Incidence of the V600K mutatio ...... ecific BRAF inhibitor PLX4032.

@ast

Incidence of the V600K mutatio ...... ecific BRAF inhibitor PLX4032.

@en

Incidence of the V600K mutatio ...... ecific BRAF inhibitor PLX4032.

@nl

type

label

Incidence of the V600K mutatio ...... ecific BRAF inhibitor PLX4032.

@ast

Incidence of the V600K mutatio ...... ecific BRAF inhibitor PLX4032.

@en

Incidence of the V600K mutatio ...... ecific BRAF inhibitor PLX4032.

@nl

prefLabel

Incidence of the V600K mutatio ...... ecific BRAF inhibitor PLX4032.

@ast

Incidence of the V600K mutatio ...... ecific BRAF inhibitor PLX4032.

@en

Incidence of the V600K mutatio ...... ecific BRAF inhibitor PLX4032.

@nl

P1433

Q34049618-17AA30CF-AB03-4441-B120-A80D89CFDD4C

P1476

Q34049618-753A20C3-B78A-40B4-A361-C9181DF46809

P2093

Q34049618-1CA65017-A8F3-4951-8CEB-EE5BA6A16037

Q34049618-4C26FE40-89B8-43D3-BD3D-5EF2FAD28E92

Q34049618-520963B2-3905-4164-85A9-5B391BF8115A

Q34049618-AAC9EDC0-639E-4BF0-A60F-26277EE04843

Q34049618-B1DEF0FB-C62A-4E8A-A373-8ECF9D056A17

Q34049618-D1547D60-0518-4917-8BFE-04F31907E6EA

Q34049618-E4D0AA7D-8A5B-4A41-A139-992DB9E269EE

P2860

Q34049618-0D1C1E50-B70C-477A-8565-0E17A099749A

Q34049618-3DC9A67F-732A-4CF9-BF8F-3A8169A2863C

Q34049618-5213D35B-9645-4DC9-AA7B-5B6862AC2573

Q34049618-93083B15-9E34-47EC-AC2F-E11AB41D81AB

Q34049618-A1483C20-4DE6-4C10-AD15-5FEFD1F95409

Q34049618-C05890C2-04EB-474A-9EB4-696B10AC81B9

Q34049618-C2971F73-6D87-444D-9A0A-62A89ACF9873

Q34049618-E1DED4E5-9735-48AE-BDE7-77C752E5D239

Q34049618-FDCF6C54-F192-4C00-8EF4-6797EFB9B91E

P2888

Q34049618-4A367FC2-E431-46E1-BB84-219F17B4EFA0

P304

Q34049618-55DABB59-09E0-44E4-AE0E-E0F257C54B11

P31

Q34049618-6B5F4F2C-B25C-44EE-9BA4-B4C71295C13A

Q34049618-eeafd879-64a9-4be7-91a3-8c14a1136add

P356

Q34049618-7FA39566-892C-44D3-91D9-2158B3418569

P478

Q34049618-F1103402-22ED-4950-8E4E-83262671ECC2

P50

Q34049618-6CD03A49-CEA0-4824-82C6-75A55FBB0DF4

Q34049618-BFF9A5C7-2371-43FD-A814-7B9541A296EA

P577

Q34049618-A63A9CD6-AE98-410B-B590-1E8606DE9E30

P5875

Q34049618-706D06D1-C33B-4BC4-9D55-56F161B62AA6

P6179

Q34049618-EF2779C2-715E-4BE9-AF56-755B0EE5BCEB

P698

Q34049618-4ACA39AF-1EB2-4F92-8193-B2C9FD4C8DC3

P921

Q34049618-581A21EA-D450-4A88-AE7B-8C574EE9CCA3

P932

Q34049618-549588C5-B3FE-4500-835D-A783ACE8F46E

P356

P1433

Journal of Translational Medicine

P1476

Incidence of the V600K mutatio ...... ecific BRAF inhibitor PLX4032.

@en

P2093

Anna C Pavlick

http://www.w3.org/2001/XMLSchema#string

Deepak Narayan

http://www.w3.org/2001/XMLSchema#string

Elaine Cheng

http://www.w3.org/2001/XMLSchema#string

Harriet M Kluger

http://www.w3.org/2001/XMLSchema#string

Jill C Rubinstein

http://www.w3.org/2001/XMLSchema#string

Ruth Halaban

http://www.w3.org/2001/XMLSchema#string

Stephan Ariyan

http://www.w3.org/2001/XMLSchema#string

P2860

PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells

BRAF and NRAS mutations in melanoma and melanocytic nevi.

B-RAF and N-RAS mutations are preserved during short time in vitro propagation and differentially impact prognosis.

BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells.

Application of a BRAF pyrosequencing assay for mutation detection and copy number analysis in malignant melanoma.

Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response.

BRAF mutations in melanocytic lesions and papillary thyroid carcinoma samples identified using melting curve analysis of polymerase chain reaction products.

BRAF mutation: a frequent event in benign, atypical, and malignant melanocytic lesions of the skin.

Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis.

P2888

P304

67

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1479-5876-8-67

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

Antonella Bacchiocchi

P577

2010-07-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45187330

http://www.w3.org/2001/XMLSchema#string

P6179

1009398527

http://www.w3.org/2001/XMLSchema#string

P698

20630094

http://www.w3.org/2001/XMLSchema#string

P921

P932

2917408

http://www.w3.org/2001/XMLSchema#string